P2Y2 receptor agonists for the treatment of dry eye disease: a review.
P2Y2 receptor agonists for the treatment of dry eye disease: a review.
复制标题
DOI：
10.2147/opth.s39699
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Skalicky SE
中科院分区：
文献类型：
--
作者：
Lau OC;Samarawickrama C;Skalicky SE
干眼病（DED）的最新进展揭示了以前未探索的药物治疗靶点。其中一种药物是地夸磷索，一种尿苷核苷酸类似物，是P2Y2受体的激动剂。几项随机对照试验表明，局部应用地夸磷索可显著改善DED的客观标志物，如角膜和结膜荧光素染色，在一些研究中，还可改善泪膜破裂时间和Schirmer试验评分。然而，这仅伴随着患者症状的部分改善。虽然来自文献的证据仍然相对有限，但早期研究表明地夸磷索在DED的管理中发挥作用。进一步的研究将有助于描述不同的DED亚组对地夸磷索的反应。地夸磷索与其他局部药物的治疗组合也值得进一步研究。
Recent advances in the understanding of dry eye disease (DED) have revealed previously unexplored targets for drug therapy. One of these drugs is diquafosol, a uridine nucleotide analog that is an agonist of the P2Y2 receptor. Several randomized controlled trials have demonstrated that the application of topical diquafosol significantly improves objective markers of DED such as corneal and conjunctival fluorescein staining and, in some studies, tear film break-up time and Schirmer test scores. However, this has been accompanied by only partial improvement in patient symptoms. Although evidence from the literature is still relatively limited, early studies have suggested that diquafosol has a role in the management of DED. Additional studies would be helpful to delineate how different subgroups of DED respond to diquafosol. The therapeutic combination of diquafosol with other topical agents also warrants further investigation.